

Zhen Zhao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1781707/publications.pdf>

Version: 2024-02-01

16
papers

653
citations

687363

13
h-index

996975

15
g-index

16
all docs

16
docs citations

16
times ranked

908
citing authors

#	ARTICLE	IF	CITATIONS
1	Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy. <i>Acta Biomaterialia</i> , 2020, 113, 501-511.	8.3	88
2	Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy. , 2019, 7, 270.		74
3	siRNA- and miRNA-based therapeutics for liver fibrosis. <i>Translational Research</i> , 2019, 214, 17-29.	5.0	65
4	Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery. <i>Molecular Pharmaceutics</i> , 2017, 14, 1517-1527.	4.6	61
5	Targeted Drug Delivery to Hepatic Stellate Cells for the Treatment of Liver Fibrosis. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 370, 695-702.	2.5	58
6	Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2016, 12, 1323-1334.	3.3	49
7	Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer. <i>Science Advances</i> , 2020, 6, eabb0616.	10.3	48
8	Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 51-61.	3.3	41
9	Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer. <i>Theranostics</i> , 2019, 9, 4508-4524.	10.0	37
10	Discovery of Peptide Ligands for Hepatic Stellate Cells Using Phage Display. <i>Molecular Pharmaceutics</i> , 2015, 12, 2180-2188.	4.6	33
11	Development of a Tumor-Responsive Nanopolyplex Targeting Pancreatic Cancer Cells and Stroma. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 45390-45403.	8.0	33
12	Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. <i>Theranostics</i> , 2020, 10, 5879-5894.	10.0	22
13	Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis. <i>Advanced Therapeutics</i> , 2019, 2, 1900046.	3.2	19
14	Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. <i>Theranostics</i> , 2021, 11, 2182-2200.	10.0	17
15	Noncovalent Attachment of Chemical Moieties to siRNAs Using Peptide Nucleic Acid as a Complementary Linker. <i>ACS Applied Bio Materials</i> , 2018, 1, 643-651.	4.6	5
16	Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 838966.	4.8	3